U.S. allowing more medical devices into Iran; Vascular Solutions sticks to its guns against Boston Scientific;

@FierceMedDev: If you missed it earlier this week, check out the "Top 10 Med Tech Investments of Q2" special report on FierceMedDev: Feature | Follow @FierceMedDev

@MarkHFierce: A blood diagnostic to predict sepsis death may be within reach. More | Follow @MarkHFierce

@DamianFierce: Cepheid wins FDA nod for combo TB test. Article | Follow @DamianFierce

 @MichaelGFierce: Silk brain implant releases seizure-reducing epilepsy drugs. Story | Follow @MichaelGFierce

> The U.S. has expanded the list of medical devices that can be exported to Iran without special permission, adding additional products such as electrocardiograph and dialysis machines. Story

> Vascular Solutions ($VASC) has no intent to back down in its legal fight with Boston Scientific ($BSX), the company said. Article

> Two Australian medical startups--focused on wound repair and heart valves--have secured significant funding from a state-level medical devices fund. Story

> The Department of Justice is looking into allegations that surgeons are striking illegal deals with medical device companies. Report

> Invacare ($IVC) is slowly working its way out from under an FDA consent decree, expecting to make its final filing with the agency in November. News

> The Washington Post's Jennifer Rubin has joined the chorus of critics calling for a repeal of the medical device tax. Column

Biotech News

@FierceBiotech: From FierceCRO.com: Icon ticks up guidance as revenue leaps another 21%. Item | Follow @FierceBiotech

@RyanMFierce: Lots of CHMP news today, notable win for Novartis in COPD and loss for Pfizer in RA. More | Follow @RyanMFierce

@EmilyMFierce: Antibody effective at fighting norovirus in chimps. Story | Follow @EmilyMFierce

> U.K. biotech PolyTherics scores $20.1M in funding for Antitope merger. More

> GlaxoSmithKline, Biogen Idec strike antibody deals with biotech startup Adimab. Article

> Vertex shares slide after FDA slaps partial hold on hepatitis C drug. Report

Pharma News

@FiercePharma: Still trending: Our special report on the Top 20 Orphan Drugs by 2018. Report | Follow @FiercePharma

@EricPFierce:  CEO Bob Hugin keeps pushing drumaker to new heights. Report | Follow @EricPFierce

@CarlyHFierce: ICYMI yesterday: GlaxoSmithKline replaces head of business in China amid bribery investigation. Article | Follow @CarlyHFierce

> Gilead earnings firm, but company gets shot in arm from Vertex setback. Item

> Humira stays strong for AbbVie as drugmaker scrambles for new offerings. Article

> EMA finds GLP-1 diabetes drugs safe to use. Report